The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback